PuraPharm Reports Reduced Losses Amid Revenue Decline in 2024

Story Highlights
  • PuraPharm operates in the Chinese medicine industry, focusing on granules and healthcare products.
  • The company reduced its net loss by 66.6% despite a 6.1% revenue decline in 2024.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
PuraPharm Reports Reduced Losses Amid Revenue Decline in 2024

PuraPharm Corp. Ltd. ( (HK:1498) ) just unveiled an announcement.

PuraPharm Corporation Limited reported its financial results for the year ending December 31, 2024, showing a revenue decline of 6.1% to HK$382,090,000 compared to the previous year. The company also reduced its net loss by 66.6% to HK$35,439,000, indicating improved financial management despite challenges in the Chinese medicine granule market, particularly in China.

More about PuraPharm Corp. Ltd.

PuraPharm Corporation Limited is a company incorporated in the Cayman Islands, operating primarily in the Chinese medicine industry. It focuses on the production and distribution of concentrated Chinese medicine granules, Chinese healthcare products, and operates Chinese medicine clinics under the brand Nong’s.

YTD Price Performance: 9.09%

Average Trading Volume: 78,824

Technical Sentiment Signal: Buy

Current Market Cap: HK$237M

See more data about 1498 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App